Countries formally adopt WHO’s Pandemic Agreement for future pandemics
After years of debates between governments, member states of the World Health Organization (WHO) have formally adopted the world's first…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Regeneron buys bankrupt 23andMe for $256m
23andMe has found itself a buyer after biotech Regeneron won an auction to buy the bankrupt genetics company for $256m.…
-
Novo Nordisk’s CEO to step down as weight loss market share plummets
Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change…
-
FDA biosimilar approvals set for record-breaking year amid US pricing reforms
2024 saw the highest number of biosimilars approved by the US Food and Drug Administration (FDA) in a calendar year,…
-
Sanofi commits ‘at least $20bn’ to US manufacturing through 2030
Sanofi has become the latest big pharma company to boost manufacturing in the US with a hefty investment as the…
-
GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire…
-
Abeona secures cash runway with $155m priority review voucher sale
US-based Abeona Therapeutics has signed a deal to sell its priority review voucher for $155m, two weeks after picking up…
-
Valneva’s chikungunya vaccine use halted in older adults amid safety concerns
The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports…
-
Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales
Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from the same period in 2024.…
-
VC firm Vivo Capital outlays $740m for biotech investment
Set against a backdrop of barren biotech investment, Vivo Capital has secured $740m to back preclinical and clinical-stage life science…